Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

Area of Science:

• Dermatology
• Immunology
• Clinical Trials

Background:

• Prurigo nodularis (PN) is a chronic inflammatory skin condition causing severe itch and nodules, unmetting the need for effective treatments.
• Current therapies for PN offer limited relief and do not fully address disease progression or patient quality of life.

Purpose of the Study:

• To assess the efficacy, safety, tolerability, and pharmacokinetics of vixarelimab in patients with moderate to severe PN.
• To evaluate the dose-dependent effects of vixarelimab administered monthly in a phase 2b clinical trial.

Main Methods:

• A 16-week, double-blind, placebo-controlled, randomized clinical trial involving 190 participants with PN.
• Participants received vixarelimab (120 mg, 360 mg, or 540 mg) or placebo subcutaneously every 4 weeks.
• Primary outcomes included changes in the Worst Itch Numeric Rating Scale (WI-NRS) and PN Investigator Global Assessment scores.

Main Results:

• Vixarelimab significantly reduced WI-NRS scores compared to placebo across all tested doses.
• Higher proportions of patients receiving vixarelimab achieved clinically meaningful itch reduction (≥4-point WI-NRS decrease) and improved PN Investigator Global Assessment scores.
• No fatal or serious drug-related adverse events were reported, indicating a favorable safety profile.

Conclusions:

• Vixarelimab demonstrated rapid, sustained, and dose-dependent clinical benefits for patients with prurigo nodularis.
• The study supports vixarelimab as a potential new therapeutic option for managing PN symptoms and improving patient outcomes.
• Further investigation in larger trials is warranted to confirm these findings and establish optimal dosing strategies.